Most analysts and doctors were expecting the FDA to seek additional information before approving Arcoxia because Merck pulled Vioxx from the market last month after a study showed it doubled patients risk of heart attacks and strokes.
Merck and federal officials should have withdrawn the painkiller Vioxx from the market as early as 2000 because studies of the drug had clearly shown that it doubled the risk of heart attacks among users, according to a study released Thursday by The Lancet, a British medical journal.
